Application seeking approval of tapinarof cream for the treatment of adults with plaque psoriasis submitted to the US FDA

The New Drug Application for the aryl hydrocarbon receptor modulating agent is supported by data from two Phase III, vehicle-controlled studies (PSOARING 1 and 2) and interim results from a 40-week open-label safety study (PSOARING 3).

Biospace Inc.